CervoMed Inc. - 8-K Filing
CervoMed reports 24-week interim biomarker data for neflamapimod in nfvPPA Phase 2a trial showing dose-dependent reduction in neurofilament light chain. (Items: 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan)
Tickers: $CRVO